While there are a substantial number of studies performed on various substances that can treat both diabetes and its comorbidities [7,8,9,10,11], there is limited knowledge of common antidiabetic drugs and other antidiabetic substances that can address various diabetic comorbidities through the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway. This evidence concerns the gene NFE2L2 and diabetes mellitus.